Antonio Ciaccio
A5071808773- Hepatitis C virus research
- Liver Disease Diagnosis and Treatment
- Hepatitis B Virus Studies
- Liver Diseases and Immunity
- Liver Disease and Transplantation
- Hepatocellular Carcinoma Treatment and Prognosis
- HIV/AIDS drug development and treatment
- Advances in Oncology and Radiotherapy
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Chronic Lymphocytic Leukemia Research
- Pediatric Hepatobiliary Diseases and Treatments
- Systemic Lupus Erythematosus Research
- Advanced Breast Cancer Therapies
- Cancer Treatment and Pharmacology
- Viral gastroenteritis research and epidemiology
- Renal Transplantation Outcomes and Treatments
- Lung Cancer Research Studies
- Diabetes Treatment and Management
- Corporate Identity and Reputation
- Immunodeficiency and Autoimmune Disorders
- Phytase and its Applications
- Cancer Mechanisms and Therapy
- Lung Cancer Treatments and Mutations
- Animal Virus Infections Studies
- Neuroendocrine Tumor Research Advances
Azienda Ospedaliera San Gerardo
2019-2024
Istituti di Ricovero e Cura a Carattere Scientifico
2023-2024
University of Milano-Bicocca
2014-2023
Ospedale Papa Giovanni XXIII
2016
University of Milan
2014
Background and Aims Liver fibrosis holds a relevant prognostic meaning in primary biliary cholangitis (PBC). Noninvasive evaluation using vibration‐controlled transient elastography (VCTE) is routinely performed. However, there limited evidence on its accuracy at diagnosis PBC. We aimed to estimate the diagnostic of VCTE assessing advanced (AF) disease presentation Approach Results collected data from 167 consecutive treatment‐naïve PBC patients who underwent liver biopsy (LB) six Italian...
Abstract Natural resistance-associated substitutions (RASs) are reported with highly variable prevalence across different HCV genotypes (GTs). Frequency of natural RASs in a large Italian real-life cohort patients infected the 4 main HCV-GTs was investigated. NS3, NS5A and NS5B sequences were analysed 1445 HCV-infected DAA-naïve patients. Sanger-sequencing performed by home-made protocols on 464 GT1a, 585 GT1b, 92 GT2c, 199 GT3a, 16 GT4a 99 GT4d samples. Overall, 20.7% (301/1455) showed...
Abstract Background & Aims The impact of chronic liver diseases (CLDs) on health‐related quality life (HRQoL) is relevant to understand the burden these conditions and inform decision‐making processes related their care. Studies simultaneously comparing HRQoL patients affected by major CLDs that general population are still lacking subject this study. Methods Using EQ‐5D‐3L questionnaire, we analysed compared data from 2962 Italian forming a representative sample (6800 individuals)....
Abstract Background Chronic hepatitis C ( CHC ) has been undertreated among elderly patients. Interferon‐free treatment represents an opportunity for these The aim of this study was to assess the cost‐effectiveness directly acting antivirals DAA s) in Methods A Markov model natural history built. This focuses on patients older than 65 years, stratified according genotype (1/4, 2 and 3), liver fibrosis METAVIR F1 F4), age frailty phenotype (robust, pre‐frail frail). s combination vs no...
In the direct-acting antiviral era, treatment of genotype-3 HCV (HCV-GT3) is still challenging. Real-life comparisons between recommended regimens, sofosbuvir (SOF)+daclatasvir (DAC), SOF/velpatasvir (VEL), glecaprevir/pibrentasvir (GLE/PIB), are scarce. We aimed at filling this data gap.Sustained virological response 12 weeks after completion (SVR12) was assessed for all HCV-GT3 patients consecutively treated within Lombardia web-based Navigatore HCV-Network; differences in SVR12 across...
Summary New and more promising therapies for chronic hepatitis C ( CHC ) genotype 1 (G1) naive patients have recently been approved in the United States Europe, several regimens are expected to become available within next years. While this scenario unfolds, it is necessary develop a rational method allocate current treatment G1 patients. We performed cost‐effectiveness analysis of boceprevir BOC )‐ telaprevir TVR )‐based triple therapy according different patients’ selection strategies. A...
The personalization of therapies in breast cancer has favoured the introduction new molecular-targeted into clinical practice. Among them, cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors have acquired increasing importance, with approval recent years palbociclib, ribociclib, abemaciclib combination endocrine therapy. Currently, no guidelines are available to monitor manage potential long-term toxicities associated use these drugs. A multidisciplinary panel European oncologists, was...
Abstract Background & Aims Chronic liver diseases (CLDs) are major health problems that require complex and costly treatments. Liver‐specific clinical outcome indicators (COIs) able to assist both clinicians administrators in improving the value of care presently lacking. The Value‐Based Medicine Hepatology (VBMH) study aims fill this gap, devising testing a set COIs for CLD, could be easily collected during practice. Here we report generated recorded patients with HBV or HCV infection...
MyD88 deficiency is a rare inborn error of immunity (IEI) characterized by susceptibility to pyogenic infections without overt signs inflammation. Half the reported patients belong Roma descent, an itinerant ethnic group living mostly in Europe, with increased risk childhood mortality due limited access healthcare services. We describe three unrelated from Campania region Italy deficiency, all belonging descent and displaying severe or recurrent early infancy. They underwent comprehensive...